Jolly Jasleen K, Simunovic Matthew P, Dubis Adam M, Josan Amandeep S, Robson Anthony G, Bellini Marco P, Bloch Edward, Georgiadis Odysseas, da Cruz Lyndon, Bridge Holly, MacLaren Robert E
Nuffield Laboratory of Ophthalmology, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom.
Oxford Eye Hospital and NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.
Front Neurosci. 2021 Oct 7;15:729807. doi: 10.3389/fnins.2021.729807. eCollection 2021.
Color vision is considered a marker of cone function and its assessment in patients with retinal pathology is complementary to the assessments of spatial vision [best-corrected visual acuity (BCVA)] and contrast detection (perimetry). Rod-cone and chorioretinal dystrophies-such as choroideremia-typically cause alterations to color vision, making its assessment a potential outcome measure in clinical trials. However, clinical evaluation of color vision may be compromised by pathological changes to spatial vision and the visual field. The low vision Cambridge Color Test (lvCCT) was developed specifically to address these latter issues. We used the trivector version of the lvCCT to quantify color discrimination in a cohort of 53 patients with choroideremia. This test enables rapid and precise characterization of color discrimination along protan, deutan, and tritan axes more reliably than the historically preferred test for clinical trials, namely the Farnsworth Munsell 100 Hue test. The lvCCT demonstrates that color vision defects-particularly along the tritan axis-are seen early in choroideremia, and that this occurs independent of changes in visual acuity, pattern electroretinography and ellipsoid zone area on optical coherence tomography (OCT). We argue that the selective loss of tritan color discrimination can be explained by our current understanding of the machinery of color vision and the pathophysiology of choroideremia.
色觉被视为视锥细胞功能的一个指标,在视网膜病变患者中对其进行评估,是对视空间视觉[最佳矫正视力(BCVA)]和对比度检测(视野检查)评估的补充。视杆-视锥细胞营养不良和脉络膜视网膜营养不良(如无脉络膜症)通常会导致色觉改变,使其评估成为临床试验中的一个潜在结局指标。然而,色觉的临床评估可能会受到空间视觉和视野病理变化的影响。低视力剑桥色觉测试(lvCCT)就是专门为解决后述问题而开发的。我们使用lvCCT的三向量版本,对53例无脉络膜症患者的色觉辨别能力进行了量化。与临床试验中历史上更常用的测试(即 Farnsworth Munsell 100 色调测试)相比,该测试能够更可靠地沿着红色盲、绿色盲和蓝色盲轴快速而精确地表征色觉辨别能力。lvCCT表明,色觉缺陷(尤其是沿着蓝色盲轴的缺陷)在无脉络膜症早期就会出现,而且这种情况的发生与视力、图形视网膜电图以及光学相干断层扫描(OCT)上的椭圆体带面积的变化无关。我们认为,蓝色盲色觉辨别能力的选择性丧失可以根据我们目前对色觉机制和无脉络膜症病理生理学的理解来解释。